8VLU image
Entry Detail
PDB ID:
8VLU
EMDB ID:
Title:
Cryo-EM structure of human HGSNAT bound with CoA
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2024-01-12
Release Date:
2024-06-26
Method Details:
Experimental Method:
Resolution:
3.12 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Heparan-alpha-glucosaminide N-acetyltransferase
Chain IDs:A (auth: B), B (auth: A)
Chain Length:663
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Structural and mechanistic insights into a lysosomal membrane enzyme HGSNAT involved in Sanfilippo syndrome.
Nat Commun 15 5388 5388 (2024)
PMID: 38918376 DOI: 10.1038/s41467-024-49614-1

Abstact

Heparan sulfate (HS) is degraded in lysosome by a series of glycosidases. Before the glycosidases can act, the terminal glucosamine of HS must be acetylated by the integral lysosomal membrane enzyme heparan-α-glucosaminide N-acetyltransferase (HGSNAT). Mutations of HGSNAT cause HS accumulation and consequently mucopolysaccharidosis IIIC, a devastating lysosomal storage disease characterized by progressive neurological deterioration and early death where no treatment is available. HGSNAT catalyzes a unique transmembrane acetylation reaction where the acetyl group of cytosolic acetyl-CoA is transported across the lysosomal membrane and attached to HS in one reaction. However, the reaction mechanism remains elusive. Here we report six cryo-EM structures of HGSNAT along the reaction pathway. These structures reveal a dimer arrangement and a unique structural fold, which enables the elucidation of the reaction mechanism. We find that a central pore within each monomer traverses the membrane and controls access of cytosolic acetyl-CoA to the active site at its luminal mouth where glucosamine binds. A histidine-aspartic acid catalytic dyad catalyzes the transfer reaction via a ternary complex mechanism. Furthermore, the structures allow the mapping of disease-causing variants and reveal their potential impact on the function, thus creating a framework to guide structure-based drug discovery efforts.

Legend

Protein

Chemical

Disease

Primary Citation of related structures